<DOC>
	<DOCNO>NCT01322789</DOCNO>
	<brief_summary>Type 1 diabetes mellitus result autoimmune destruction insulin produce pancreatic Î²-cells . The autoimmune response begin month even year presentation hyperglycemic symptom . Previous study autoimmune disease acute inflammatory disease test effect infusion mesenchymal stem cell show promising result regulate immune system promote degree disease control . The aim study determine safety efficacy intravenous infusion mesenchymal stem cell newly diagnose type 1 diabetic patient .</brief_summary>
	<brief_title>Safety Efficacy Mesenchymal Stem Cells Newly-diagnosed Type 1 Diabetic Patients</brief_title>
	<detailed_description>Patients 12 35 year old type I diabetes mellitus prove anti-pancreatic beta cell antibody recently diagnose ( less 6 week ) include study . First , bone marrow derive adult mesenchymal stem cell collect first degree relative culture . After , patient receive 4 intravenous infusion 1 week apart follow 4 infusion 4 month apart .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Type 1 diabetes mellitus diagnose clinical/metabolic parameter positive antiGAD antibody Less 6 week diagnosis Previous diabetic ketoacidosis Pregnancy Severe psychiatric disorder Severe organic impairment ( renal , hepatic , cardiac , pulmonary ) Active infectious disease Previous present neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Autologous stem cell transplantation</keyword>
	<keyword>Autoimmune disease</keyword>
</DOC>